Dr. Li is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
19 Bradhurst Ave, Suite 3850S
Hawthorne, NY 10532Phone+1 914-345-1313Fax+1 914-345-5004
Summary
- Dr. Jin Li is a neurologist in Hawthorne, NY and is affiliated with Westchester Medical Center. She received her medical degree from Beijing Medical University and has been in practice 24 years. She specializes in neuromuscular medicine and headache medicine.
Education & Training
Westchester Medical CenterResidency, Neurology, 1999 - 2002- Westchester Medical CenterInternship, Internal Medicine, 1998 - 1999
Beijing Medical UniversityClass of 1993
Certifications & Licensure
NY State Medical License 2002 - 2025
OH State Medical License Active through 2014- American Board of Psychiatry and Neurology Neurology
- American Board of Psychiatry and Neurology Neuromuscular Medicine
Publications & Presentations
PubMed
- 161 citationsPrecise RNA editing by recruiting endogenous ADARs with antisense oligonucleotidesTobias Merkle, Sarah Merz, Philipp Reautschnig, Andreas Blaha, Qin Li
Nature Biotechnology. 2019-01-28 - 100 citationsEfficient and precise editing of endogenous transcripts with SNAP-tagged ADARs.Paul Vogel, Matin Moschref, Qin Li, Tobias Merkle, Karthika D. Selvasaravanan
Nature Methods. 2018-07-02 - 397 citationsDynamic landscape and regulation of RNA editing in mammalsMeng How Tan, Qin Li, Raghuvaran Shanmugam, Robert Piskol, Jennefer N. Kohler
Nature. 2017-10-11
Press Mentions
Nimotuzumab May Improve Overall Survival in Patients with KRAS Wild-Type Advanced Pancreatic CancerJune 3rd, 2022- Yingli Pharma Announces Presentations on the Phase 1 Trials of Linperlisib, a PI3Kδ Selective Inhibitor, and YL-13027, an Oral TGFβR1 Inhibitor, at the American Society for Clinical Oncology 2021 Annual MeetingJune 4th, 2021
- Henlius Plans to File the NDA of Novel Anti-PD-1 mAb HLX10 for the Treatment of MSI-H Solid Tumours, the Phase 2 Clinical Trial Has Met the Primary EndpointMarch 29th, 2021
- Join now to see all
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
